Abnormal hepatic energy homeostasis in type 2 diabetes

Increased hepatocellular lipids relate to insulin resistance and are typical for individuals with type 2 diabetes mellitus (T2DM). Steatosis and T2DM have been further associated with impaired muscular adenosine triphosphate (ATP) turnover indicating reduced mitochondrial fitness. Thus, we tested the hypothesis that hepatic energy metabolism could be impaired even in metabolically well‐controlled T2DM. We measured hepatic lipid volume fraction (HLVF) and absolute concentrations of γATP, inorganic phosphate (Pi), phosphomonoesters and phosphodiesters using noninvasive 1H/ 31P magnetic resonance spectroscopy in individuals with T2DM (58 ± 6 years, 27 ± 3 kg/m 2), and age‐matched and body mass index–matched (mCON; 61 ± 4 years, 26 ± 4 kg/m 2) and young lean humans (yCON; 25 ± 3 years, 22 ± 2 kg/m 2, P < 0.005, P < 0.05 versus T2DM and mCON). Insulin‐mediated whole‐body glucose disposal (M) and endogenous glucose production (iEGP) were assessed during euglycemic‐hyperinsulinemic clamps. Individuals with T2DM had 26% and 23% lower γATP (1.68 ± 0.11; 2.26 ± 0.20; 2.20 ± 0.09 mmol/L; P < 0.05) than mCON and yCON individuals, respectively. Further, they had 28% and 31% lower Pi than did individuals from the mCON and yCON groups (0.96 ± 0.06; 1.33 ± 0.13; 1.41 ± 0.07 mmol/L; P < 0.05). Phosphomonoesters, phosphodiesters, and liver aminotransferases did not differ between groups. HLVF was not different between those from the T2DM and mCON groups, but higher (P = 0.002) than in those from the yCON group. T2DM had 13‐fold higher iEGP than mCON (P < 0.05). Even after adjustment for HLVF, hepatic ATP and Pi related negatively to hepatic insulin sensitivity (iEGP) (r =‐0.665, P = 0.010, r =‐0.680, P = 0.007) but not to whole‐body insulin sensitivity. Conclusion: These data suggest that impaired hepatic energy metabolism and insulin resistance could precede the development of steatosis in individuals with T2DM. (HEPATOLOGY 2009.)

[1]  R. Pandey,et al.  Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo ((31)P) phosphorus magnetic resonance spectroscopy. , 2009, Atherosclerosis.

[2]  M. Roden,et al.  Ectopic lipids and organ function , 2009, Current opinion in lipidology.

[3]  V. Darley-Usmar,et al.  High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo , 2008, The Biochemical journal.

[4]  S. Schinner Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[5]  E. Moser,et al.  Three‐dimensional high‐resolution magnetic resonance spectroscopic imaging for absolute quantification of 31P metabolites in human liver , 2008, Magnetic resonance in medicine.

[6]  F. Schick,et al.  (1)H MR spectroscopy of skeletal muscle, liver and bone marrow. , 2008, European journal of radiology.

[7]  A. Lonardo,et al.  Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. , 2008, Clinical science.

[8]  E Moser,et al.  Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment , 2008, NMR in biomedicine.

[9]  S. Mantena,et al.  Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. , 2008, Free radical biology & medicine.

[10]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[11]  M. Wolzt,et al.  Muscle Mitochondrial ATP Synthesis and Glucose Transport/Phosphorylation in Type 2 Diabetes , 2007, PLoS medicine.

[12]  Zdeněk Tošner,et al.  Application of two-dimensional CSI for absolute quantification of phosphorus metabolites in the human liver , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[13]  D. Graveron-Demilly,et al.  Java-based graphical user interface for the MRUI quantitation package , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[14]  S. Takase,et al.  Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis. , 2007, Alcoholism, clinical and experimental research.

[15]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[16]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[17]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[18]  Peter Nowotny,et al.  Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. , 2006, Diabetes.

[19]  K. Petersen,et al.  Decreased Insulin-Stimulated ATP Synthesis and Phosphate Transport in Muscle of Insulin-Resistant Offspring of Type 2 Diabetic Parents , 2005, PLoS medicine.

[20]  Jeanne M Clark,et al.  Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[21]  F. Schick,et al.  Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[22]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[23]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[24]  C. Cobelli,et al.  Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. , 2004, Diabetes.

[25]  D. Pessayre,et al.  Mitochondrial injury in steatohepatitis , 2004, European journal of gastroenterology & hepatology.

[26]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[27]  E. Björnsson,et al.  High prevalence of metabolic complications in patients with non‐alcoholic fatty liver disease , 2004, Scandinavian journal of gastroenterology.

[28]  J. Arenas,et al.  Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.

[29]  V. P. Chacko,et al.  Hepatic ATP Reserve and Efficiency of Replenishing: Comparison Between Obese and Nonobese Normal Individuals , 2003, American Journal of Gastroenterology.

[30]  M. Roden,et al.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.

[31]  C. Bogardus,et al.  High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.

[32]  G. Pacini,et al.  Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.

[33]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[34]  M. Oudkerk,et al.  Decreased energy and phosphorylation status in the liver of lung cancer patients with weight loss. , 2000, Journal of hepatology.

[35]  H. Cortez‐Pinto,et al.  Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.

[36]  J. Parks,et al.  Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.

[37]  F. Schick,et al.  Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.

[38]  M. Oudkerk,et al.  Understanding the discrepancies between 31P MR spectroscopy assessed liver metabolite concentrations from different institutions. , 1998, Magnetic resonance imaging.

[39]  Vanhamme,et al.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.

[40]  D. Aust,et al.  Defects of the respiratory chain in the normal human liver and in cirrhosis during aging , 1997, Hepatology.

[41]  R. Holman,et al.  UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. , 1997, The Journal of clinical endocrinology and metabolism.

[42]  Jimmy D Bell,et al.  Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. , 1996, Gut.

[43]  T. Brown,et al.  Molar Quantitation of Hepatic Metabolites In Vivo in Proton‐decoupled, Nuclear Overhauser Effect Enhanced 31P NMR Spectra Localized by Three‐dimensional Chemical Shift Imaging , 1996, NMR in biomedicine.

[44]  C. Tiribelli,et al.  Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis , 1995, Journal of magnetic resonance imaging : JMRI.

[45]  D. Menon,et al.  Effect of functional grade and etiology on in vivo hepatic phosphorus‐31 magnetic resonance spectroscopy in cirrhosis: Biochemical basis of spectral appearances , 1995, Hepatology.

[46]  C. Muhle,et al.  In Vivo P‐31-MR‐Spectroscopy of Focal Hepatic Lesions: Effectiveness of Tumor Detection in Clinical Practice and Experimental Studies of Surface Coil Characteristics and Localization Technique , 1995, Investigative radiology.

[47]  R. Buchli,et al.  Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part II: Muscle, liver, kidney , 1994, Magnetic resonance in medicine.

[48]  山根 豊 Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection , 1994 .

[49]  W G Bradley,et al.  Quantitative P‐31 MR spectroscopy of the liver in alcoholic cirrhosis , 1992, Journal of magnetic resonance imaging : JMRI.

[50]  B. Lauterburg,et al.  Assessment of mitochondrial function in vivo with a breath test utilizing α—ketoisocaproic acid , 1989, Hepatology.

[51]  M W Weiner,et al.  Alcoholic liver disease: quantitative image-guided P-31 MR spectroscopy. , 1989, Radiology.

[52]  B. Lauterburg,et al.  Assessment of mitochondrial function in vivo with a breath test utilizing alpha-ketoisocaproic acid. , 1989, Hepatology.

[53]  J. S. Cohen,et al.  Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. , 1987, The Journal of biological chemistry.

[54]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.